Could a common diabetes drug help fight brain tumors?

NCT ID NCT07541781

Recruiting now Disease control Sponsor: Kailin Yang, MD, PhD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether sitagliptin, a drug used for diabetes, can help treat recurrent grade 4 glioma (a severe brain cancer) when combined with the standard drug bevacizumab. The study involves 45 adults whose cancer has returned after initial treatment. Researchers aim to find the safest dose of sitagliptin and see if it changes certain immune cells in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sitagliptin (a diabetes drug) combined with bevacizumab (Avastin, a cancer drug)
What this could lead to: If it works, this could point toward a new treatment option for recurrent glioblastoma, a tough-to-treat brain cancer.
What could go wrong: This is a very early Phase 1 trial with only 45 people. The main goal is safety and dosing, not yet proof of effectiveness. Side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain glioblastoma brain glioma glioblastoma glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA GLIOMA GRADE 4 MALIGNANT GLIOMA OF BRAIN (DISORDER) RECURRENT GLIOBLASTOMA RECURRENT GLIOMA

Contacts and locations

Locations

University of Iowa Health Care
RECRUITING

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.